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Abstract
Amniotic fluid embolism (AFE) is a rare complication of pregnancy often result-
ing in catastrophic maternal and fetal outcomes. Given the rarity of this condition, 
there is a wide variation in reported incidence of amniotic fluid embolism. The 
pathophysiology of AFE is not completely understood. It is thought to be the result 
of a breach of the maternal-fetal barrier resulting in an abnormal maternal proin-
flammatory response. AFE presents as a sudden onset of hypoxia, hypotension, and 
coagulopathy during labor and delivery or in the immediate postpartum period. 
Abnormalities in the fetal heart tracing are almost always present. Risk factors often 
include advanced maternal age, induction of labor, cesarean delivery, operative vag-
inal delivery, placenta previa, and placental abruption. The diagnosis of amniotic 
fluid embolism is made based on clinical presentation. There are no laboratory tests 
that confirm the diagnosis of AFE; however, serum tryptase levels, complement 
levels, zinc coproporphyrin, and serum sialyl Tn (STn) may support the diagnosis. 
Management of women with AES is supportive and most often requires admission 
to an intensive care unit. Although maternal morbidity and mortality remain high, 
advances in medical technology and improvements in obstetrical critical care and 
early diagnosis of AFE have improved outcomes.
Keywords: amniotic fluid embolism, maternal mortality, DIC, pregnancy,  
hypoxia, shock, hypotension
1. Introduction
Amniotic fluid embolism (AFE) is a rare pregnancy complication often resulting 
in significant maternal and fetal/neonatal morbidity and mortality. AFE is one of 
the leading causes of maternal mortality in developed countries and is most often 
diagnosed at the time of delivery or in the immediate postpartum period. The 
term amniotic fluid embolism developed from a theory based on a small subset 
of patients who were deemed to have died as result of an embolic event associated 
with amniotic fluid. This theory has largely been discredited by a growing body 
of evidence that suggests AFE is most likely the result of an abnormal proinflam-
matory response in the host [1]. Given the rarity of this syndrome, the reported 
incidence varies greatly from 1.9 per 100,000 in the United Kingdom to as high as 
6.1 per 100,000 in Australia [1, 2]. However, even with prompt diagnosis and timely 
treatment, maternal mortality rates remain high.
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2. Pathophysiology
AFE was first described in the 1920s by J.R. Meyer. It was later recognized as a 
syndrome in 1941 when Steiner and Lushbaugh reported autopsy findings of 32 
women who died suddenly during childbirth. The common histopathological find-
ing among these women was the presence of amniotic fluid debris in the pulmonary 
vasculature [1]. Therefore, the historical hypothesis was based on an obstruction of 
the pulmonary arteries from amniotic fluid or fetal debris [1, 3]. Medical advance-
ments in the 1980s allowed for more frequent use of the pulmonary artery catheter 
to obtain arterial histologic specimens from living patients [1]. There were several 
reports of pathologic findings that were previously thought to be diagnostic of AFE 
found in pregnant women that did not have AFE. These findings called into ques-
tion previous cases diagnosed as AFE that were based solely on pathologic findings.
The second and more commonly accepted theory is that AFE results from a 
complex sequence of reactions involving an abnormal activation of proinflamma-
tory mediators in the host leading to an immunologic response [1–7]. This response 
is similar to the systemic inflammatory response syndrome (SIRS). Amniotic fluid 
contains several procoagulant factors including platelet-activating factor, leukotrienes, 
bradykinin, cytokines, thromboxane, and arachidonic acid, which aids in the under-
standing of why disseminated intravascular coagulation (DIC) is observed in 80% or 
more of women diagnosed with AFE [1, 7, 8]. In conjunction with these responses, a 
profound hemodynamic change leads to the maternal collapse and death in patients 
with AFE. Thus, during the first minutes, a sudden increase in pulmonary vascular 
resistance as a result of an inflammatory/anaphylactoid vasoconstriction leads to a right 
ventricular dysfunction with dilation of the right ventricular chambers, with a left shift 
of the interventricular septum and a decrease of the left ventricular filling pressures, 
with hypotension and cardiovascular collapse [9]. This severe pulmonary vasoconstric-
tion produces an oxygen shunt, with ventilation-perfusion mismatching and severe 
hypoxia. Finally, left ventricular failure may be present as a consequence of myocardial 
injury secondary to some inflammatory mediators or myocardial ischemia [10].
Complement activation is thought by some to play a role in the pathophysiol-
ogy of AFE. Virtually all patients diagnosed with AFE develop some degree of 
acute respiratory distress syndrome (ARDS). Various case series evaluating serum 
complement levels in patients with AFE have noted significantly decreased levels 
of C3 and C4 compared to a control group of normal laboring patients who all had 
complement levels within the normal range [7]. Decreased levels of C3 are thought 
to be consistent with complement activation.
3. Incidence and risk factors
3.1 Incidence
The true incidence of amniotic fluid embolism is unknown. Discrepancies in 
diagnosis as well as inconsistencies in reporting practices lead to a wide range of 
estimates. AFE incidence ranges between 1 in 8000 and 1 in 80,000 pregnancies 
[8, 11, 12]. In 2012, Knight et al. reviewed available data sources from Australia, 
Canada, the Netherlands, the United Kingdom, and the United States to investigate 
incidence rates and identify variations in methodology in diagnosis of AFE. Their 
analysis found a reported incidence of AFE ranging from 1.9 cases per 100,000 in 
the United Kingdom to 6.1 cases per 100,000 cases in Australia. Differences in the 
reported incidence were attributed to a lack of internationally accepted diagnostic 




Review of various data registries reveals a wide range of conflicting data regard-
ing identifiable risk factors for AFE. Historically, risk factors associated with 
AFE included situations where there was an increased likelihood of exchange of 
maternal and fetal components [1, 2, 13]. Events such as cesarean delivery, operative 
vaginal delivery, cervical trauma, placenta previa, and abruption were frequently 
reported [9, 13–16].
Knight et al. in 2012 reviewed data sources on incidence of AFE in Australia, 
Canada, the Netherlands, the United Kingdom, and the United States. Where data 
was available, they also examined risk factors associated with AFE. There were 
only two associations that were consistent across all five countries: induction of 
labor and maternal age [2]. In the Netherlands the association with age was not 
statistically significant. This may be a result of the limited power of the study 
given that all reported cases occurred in women who were 29 years of age or older. 
The data from Canada showed an association between AFE and all methods of 
medical induction of labor, while in the United Kingdom, there was only a statisti-
cally significant association with induction of labor using vaginal prostaglandins 
[2]. In the United States, all methods of induction of labor showed an increased 
odds ratio; however, this was not statistically significant [2]. Increased odds of 
AFE associated with placental previa and placental abruption was also observed. 
In the United Kingdom there was a statistically significant association between 
cesarean section when the amniotic fluid embolism occurred after delivery. There 
was no association with forceps or vacuum delivery; however, only a small subset 
of women underwent an operative vaginal delivery, so there is limited power to 
detect this association [2].
Another group of researchers who conducted a population-based cohort study 
on 3 million birth records in the United States from 1999 to 2003 found AFE was 
associated with maternal age greater than 35 (OR 2.2, 95% CI 1.5–2.1). However, 
they did not find that AFE was significantly associated with induction of labor. 
They also reported an association of placenta previa (OR 30.4, 95% CI 15.4–60.1) 
and cesarean delivery (OR 5.7, 95% CI 3.7–8.7) [16].
Maternal risk factors [1, 3, 5, 6, 8, 9, 11, 13–16]:
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Obstetrical factors [1, 3, 5, 6, 8, 9, 11, 13–16]:
• Induction or augmentation of labor
• Cesarean section
• Cervical or abdominal trauma
• Premature rupture of membranes





There should be a high level of suspicion of AFE for a pregnant or postpartum 
woman with an acute onset of cardiopulmonary compromise, DIC, and altered 
mental status. The diagnosis of AFE is one of exclusion and is based upon clinical 
findings of sudden onset of hypoxia, cardiovascular compromise, and/or coagu-
lopathy. The differential diagnosis of AFE includes, but is not limited to, pulmonary 
embolism, anaphylaxis, placental abruption, myocardial infarction, eclampsia, 
aspiration, and septic shock [1, 4, 5]. To date there are no specific laboratory tests 
available to diagnosis AFE. Some recent publications have suggested an insulin-like 
growth factor binding protein-1 as a useful biomarker for AFE diagnosis, with high 
sensitivity and specificity; however, this is not extensively used [6].
The Society of Maternal-Fetal Medicine (SMFM) and the Amniotic Fluid 
Embolism Foundation proposed a definition of AFE based on four diagnostic crite-
ria, which are all required to be present. This definition was specifically developed 
for research purposes.
1. “Sudden onset of cardiorespiratory arrest, or both hypotension (systolic blood 
pressure < 90 mm Hg) and respiratory compromise (dyspnea, cyanosis, or 
peripheral capillary oxygen saturation < 90%)
2. Documentation of overt DIC after appearance of these initial signs or 
symptoms, using this scoring system of the Scientific and Standardization 
Committee on DIC of the International Society on Thrombosis and Hemostasis 
(ISTH), modified for pregnancy. Coagulopathy must be detected before loss 
of sufficient blood to itself account for dilutional or shock-related consumptive 
coagulopathy
3. Clinical onset during labor or within 30 minutes of delivery of placenta
4. Absence of fever (≥38°C) during labor” [6, 14].
Although there are no specific tests that are currently recommended to confirm 
the diagnosis of amniotic fluid embolism, there are test that may help to support the 
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diagnosis. Initial evaluation should always include assessment of arterial blood gas to 
determine the degree of hypoxemia. In addition to arterial blood gas measurements, 
serial complete blood counts and coagulation studies should be trended in order to 
detect early coagulopathy [9]. These studies can aid in the early identification of 
DIC. Abnormalities often include a prolonged prothrombin time (PT) which is due 
to consumption of clotting factors as well as a decreased fibrinogen. Intervention is 
often indicated if the PT is 1.5 times the normal limit. Activated partial thrombo-
plastin time may not be as helpful as values may be within normal reference range.
Additional laboratory tests proposed include various markers of C3 and C4 
complement activation, serum tryptase, insulin-like growth factor binding pro-
tein-1, urinary histamine, and arachidonic acid metabolites [1, 4, 9]. Tryptase is 
a serine protease that has a half-life of several hours and has been useful in the 
diagnosis of anaphylaxis. Given the similarities of the reported pathophysiology of 
AEF and anaphylaxis, elevated levels of serum tryptase may aid in diagnosis. There 
have been reports of the use of immunostaining techniques of the monoclonal 
TKH-2 antibodies in maternal serum and lung tissue. Although data is limited, 
there are a few studies that have evaluated the use of serum sialyl Tn (STn) which 
is a fetal antigen in meconium as well as amniotic fluid that can be detected with 
TKH-2 monoclonal antibodies. TKH-2 reacts with fetal components (meconium 
and mucin) which stain the lung tissue of women with AFE [4, 5, 9]. Researchers 
found that serum levels of sialyl Tn greater than 50 U/ml had a sensitivity between 
78 and 100% and a specificity between 97 and 99% [9]. Another biomarker of 
interest is zinc coproporphyrin, which is also a component of amniotic fluid found 
in maternal serum and can be elevated in women with AFE [1, 4, 9].
Radiographic findings are nonspecific and not diagnostic. The most common 
radiographic abnormalities in AFE are bilateral interstitial and alveolar infiltrates 
with areas of increased opacity which is indistinguishable from pulmonary edema 
[4, 9]. The use of bedside transesophageal echocardiography may aid in early 
identification of acute pulmonary vasoconstriction or left heart failure precipitating 
earlier intervention [4, 9].
5. Clinical presentation
The classic presentation of AFE is often described as an acute onset of respira-
tory distress, hypoxia, hypotension (including cardiac arrest), seizures, and DIC 
either during labor, during delivery, or in the immediate postpartum period. If AFE 
occurs during labor, electronic fetal heart tracings frequently demonstrate acute 
changes characteristic of fetal hypoxia. There is often a rapid progression from the 
time of onset of the initial signs and symptoms to end organ damage and death. 
Severe consumptive coagulopathy is seen in only two obstetric conditions, AFE and 
massive placental abruption [4]. DIC is present in approximately 80% of patients 
with AFE and may develop at any time; however, half of affected patients develop 
coagulopathy within 4 hours of initial symptoms [2].
6. Management
The management of women diagnosed with AFE is centered on supportive 
care. Unfortunately, even with prompt recognition and appropriate treatment, 
maternal morbidity and mortality remain high. The Society for Maternal-Fetal 
Medicine (SMFM) recommends a multidisciplinary team approach consisting of 
anesthesiology, critical care medicine, respiratory therapy, and maternal-fetal 
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medicine [6]. Treatment is initially focused on maternal cardiopulmonary stabili-
zation with a goal to limit end organ damage [2]. Intravenous access with two large 
bore IVs should be obtained in anticipation of the need for aggressive fluid resus-
citation. Hypotension is corrected with optimization of preload via rapid infusion 
of isotonic crystalloid and colloid solutions [4, 8, 9]. Transthoracic or transesopha-
geal echocardiography is helpful to guide fluid therapy [4–6, 9]. Placement of an 
arterial line and pulmonary catheter if feasible is also useful. In addition to IVF 
resuscitation, transfusions of packed red blood cells are necessary to aid in hypo-
tension as well as restoration of oxygen carrying capacity. The use of vasopressors 
and or inotropic support is often necessary. A central line should be placed for 
infusion of vasopressors as well as monitoring. Following stabilization of the 
patient, admission to an intensive care unit is recommended for close monitoring. 
Initial laboratory testing should include a CBC, arterial blood gas, electrolytes, and 
a coagulation panel.
6.1 Hypoxia
Acute hypoxia is frequently the first sign of AFE and has been reported to be 
present in >90% of patients according to the AFE National Registry [2]. Maternal 
oxygenation should be monitored by pulse oximetry. The degree of respiratory 
compromise will determine the approach for oxygen delivery. Regardless of the 
route of delivery, oxygen should be administered immediately and judiciously. 
Intubation is often necessary but may not be required in all cases.
6.2 Cardiac arrest
The early phase of AFE often consists of right ventricular failure which can be identi-
fied with the use of transthoracic or transesophageal echocardiography [9, 13]. Findings 
of echocardiography may include a dilated right ventricle and a collapsed left ventricle 
with leftward deviation of the interventricular septum [9, 13]. Cardiopulmonary 
resuscitation (CPR) should be initiated immediately with priority given to high-quality 
chest compressions before rescue breaths [6]. Standard basic life support (BLS) and 
advanced cardiac life support (ACLS) protocols should also be initiated [1, 6]. If the 
fetus is undelivered and has reached a gestational age of potential viability (≥23 weeks), 
immediate delivery is indicated [1, 2, 6]. Preparation for a perimortem cesarean section 
should occur simultaneously with the initiation of CPR [1, 10]. The undelivered patient 
should be placed in a left lateral tilt that displaces the uterus to avoid compression of 
the aorta and IVC [2, 6]. Patients that progress to cardiac arrest have a dismal prognosis 
compared to their counterparts with AFE that do not develop cardiac arrest.
6.3 Coagulopathy
Hemorrhage with DIC requires initiation of a massive transfusion protocol. 
Correcting the coagulopathy may require aggressive repletion of red blood cells 
and blood products, fresh frozen plasma, platelets, and/or cryoprecipitate. 
Consideration should be given to arterial catheterization if possible, which allows 
for accurate blood pressure monitoring as well as blood sampling [5]. The use of 
recombinant factor VIIa has been reported in the literature, though data on its use 
is limited and conflicting. Research suggests that the use of recombinant factor VIIa 
most likely should be reserved for cases where conventional resuscitative measures 
fail [1]. Increasing evidence suggests the use of thrombelastometry for early iden-
tification of patients with AFE but also to guide management, providing a point of 
care for monitoring during the hemorrhagic phase of AFE [17].
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Additional approaches to treatment of amniotic fluid embolism reported in 
the literature include extracorporeal membrane oxygenation (ECMO), plasma 
exchange transfusions, cardiopulmonary bypass, uterine artery embolization, 
continuous hemofiltration, pulmonary artery thromboembolectomy, intra-aortic 
balloon pump with ECMO, high-dose corticosteroids, C1 esterase inhibitors, and 
serum protease inhibitor therapy. There are no high-quality data available for many 
of the treatment approaches mentioned.
Aprotinin is a single-chain polypeptide derived from bovine tissues and is an 
inhibitor of proteolytic enzymes [9]. It is used in the treatment of hemorrhage 
associated with raised plasma concentrations of plasmin and may be effective for 
hemorrhage associated with AFE. Other fibrinolytic agents like tranexamic acid 
and aminocaproic acid are used in the management of hemorrhage and may be 
useful. Hysterectomy is necessary in individuals when uterine hemorrhage persists 
despite more conservative measures.
7. Outcomes
Mortality associated with amniotic fluid embolism appears to have declined 
which is likely associated with early diagnosis as well as improvements in critical 
care [4, 5, 9]. Disease severity (i.e., the presence or absence of cardiac arrest) is 
closely related to prognosis. Mortality rates vary greatly depending upon criteria 
used for diagnosis of AFE but have been reported as high as 60–70% [1, 9, 14]. The 
use of population-based studies appears to provide the best available evidence of 
the mortality rate associated with AFE. Analysis of a collection of 9 population-
based studies published since 1999 which included more than 17 million births in 
8 countries and 751 cases of amniotic fluid embolism revealed an overall mortality 
rate of 20.3% [7]. Morbidity, however, remains extremely high and can include 
serious neurologic impairment, renal failure, cardiac failure, arrhythmias, and 
myocardial infarction [5, 9].
Although limited data is available, neonatal survival rates are reported in the 
range of 70% [4, 5, 9]. Survival is dependent upon timing of delivery relative to 
onset of symptoms. Neonates delivered prior to onset of symptoms or soon after 
onset of symptoms have lower rates of morbidity and mortality.
There is no data to suggest that survivors of AFE have an increased risk of 
recurrence in a subsequent pregnancy. However, the risk of recurrence is unknown. 
There have been published case reports of successful pregnancies following an AFE.
8. Summary
Amniotic fluid embolism remains an elusive disease with catastrophic outcomes. 
The pathophysiology remains unclear even with new research developments 
over the last 10 years. However, the theory that the syndrome may be caused by 
an abnormal maternal proinflammatory response incited by fetal components is 
promising. The variation in maternal response to fetal and amniotic components 
present in the maternal circulation may provide useful information and requires 
further investigation. Various laboratory tests and biomarkers have been proposed 
that may aid in diagnosis of an AFE; however, there is no gold standard diagnostic 
test available at this time. AFE remains a diagnosis of exclusion and relies on clinical 
judgment. A high level of suspicion in laboring or postpartum women with acute 
cardiopulmonary compromise or coagulopathy is required for optimal maternal 
and fetal outcomes.
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